Extrascleral Extension of Uveal Melanoma Along Intravitreal Needle Tracts Associated With Periodic Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration

Hursuong Vongsachang; Anna M Stagner; Mary E Aronow; Natalie Wolkow

doi:10.1001/jamaophthalmol.2023.2521

Extrascleral Extension of Uveal Melanoma Along Intravitreal Needle Tracts Associated With Periodic Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration

JAMA Ophthalmol. 2023 Aug 1;141(8):801-803. doi: 10.1001/jamaophthalmol.2023.2521.

Authors

Hursuong Vongsachang¹, Anna M Stagner², Mary E Aronow³, Natalie Wolkow^{1

2}

Affiliations

¹ Ophthalmic Plastic Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston.
² David G. Cogan Laboratory of Ophthalmic Pathology, Massachusetts Eye and Ear, Harvard Medical School, Boston.
³ Retina Service, Massachusetts Eye and Ear, Harvard Medical School, Boston.

PMID: 37347465
DOI: 10.1001/jamaophthalmol.2023.2521

No abstract available

Plain language summary

This case report describes a 94-year-old man who was seen for evaluation of a left choroidal mass after receiving periodic anti–vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration.

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Choroidal Neovascularization* / drug therapy
Endothelial Growth Factors / therapeutic use
Humans
Intravitreal Injections
Macular Degeneration* / drug therapy
Ranibizumab / therapeutic use
Retrospective Studies
Wet Macular Degeneration* / drug therapy

Substances

Endothelial Growth Factors
Ranibizumab
Angiogenesis Inhibitors

Supplementary concepts

Uveal melanoma